Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

The National Institute for Health and Care Excellence (NICE) provides guidance to improve health and social care in England and Wales. NICE invited Daiichi Sankyo to submit evidence for the use of trastuzumab deruxtecan (T-DXd) for treating human epidermal growth factor 2 (HER2)-positive unresectabl...

Descripción completa

Detalles Bibliográficos
Autores principales: Houten, Rachel, Fleeman, Nigel, Mahon, James, Chaplin, Marty, Edwards, Katherine, Beale, Sophie, Boland, Angela, Dundar, Yenal, Marsden, Ashley, Malik, Zafar, Palmieri, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169930/
https://www.ncbi.nlm.nih.gov/pubmed/37084172
http://dx.doi.org/10.1007/s41669-023-00405-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169930/
https://www.ncbi.nlm.nih.gov/pubmed/37084172
http://dx.doi.org/10.1007/s41669-023-00405-2

Ejemplares similares